Asset
BAMOCAFTOR
Vertex Pharmaceuticals Incorporated Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03447249 | phase3 | completed | 2018-03-07 | 2019-02-05 | Vertex Pharmaceuticals Incorporated | A Phase 3 Study of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF) |
| NCT03447262 | phase3 | terminated | 2018-07-13 | 2020-09-09 | Vertex Pharmaceuticals Incorporated | A Study Evaluating the Long Term Safety and Efficacy of VX-659 Combination Therapy |
| NCT03224351 | phase2 | completed | 2017-08-08 | 2018-02-28 | Vertex Pharmaceuticals Incorporated | A Study Evaluating the Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis |
| NCT03460990 | phase3 | completed | 2018-05-01 | 2018-09-26 | Vertex Pharmaceuticals Incorporated | A Study of VX-659 Combination Therapy in CF Subjects Homozygous for F508del (F/F) |
| NCT03029455 | phase1 | completed | 2016-11-01 | 2017-08-01 | Vertex Pharmaceuticals Incorporated | A Study to Evaluate Safety and Pharmacokinetics of VX-659 in Healthy Subjects and in Adults With Cystic Fibrosis |
FDA applications (0)
This company has no applications containing this asset.